论文部分内容阅读
抗癌新药 Epipodophyllotoxin(EPEG),化学名为4’-去甲基鬼臼毒9-(4,6-0-2-亚乙基-β-D-吡喃葡萄糖甙),系一种半合成的鬼臼毒衍生物,对实验性肿瘤 S-180,艾氏腹水癌和瓦克氏癌肉瘤256有效,并显著抑制白血病 L1210及脑部接种的 L1210。对组织培养的肥大细胞瘤 P815只需0.046微克-毫升就可产生50%抑制率。其作用原理主要是抑制中期分裂细胞,近来也有认为是对 G_2期细胞起作用。临床试验正在开始,给药方案为连续7天、每周二次共三周或每周一次共六周三种不同的方式进行比
Anti-cancer drug Epipodophyllotoxin (EPEG), chemical name 4’-demethylphosporicin 9-(4,6-0-2-ethylidene-β-D-glucopyranoside), is a semi-synthetic The podophyllotoxin derivative is effective against experimental tumors S-180, Ehrlich ascites carcinoma, and WACKER sarcoma 256, and significantly inhibits leukemia L1210 and brain-inoculated L1210. For tissue cultured mast cell tumors, P815 requires only 0.046 μg-mL to produce 50% inhibition. Its principle of action is mainly to inhibit the metaphase dividing cells, and it has recently been thought that it acts on the G2 phase cells. Clinical trials are beginning. Dosing schedules are three different ways: continuous 7 days, weekly 2 weeks, or weekly 6 weeks.